Neurodegeneration refers to the progressive loss of neuronal structure and function, leading to neuronal death. This umbrella term encompasses a heterogeneous group of disorders characterized by the gradual decline in specific populations of neurons, resulting in cognitive, motor, and autonomic dysfunction. The major neurodegenerative diseases include Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), Huntington's disease (HD), frontotemporal dementia (FTD), and multiple system atrophy (MSA), among others. This page provides a comprehensive overview of the molecular mechanisms, disease categories, biomarkers, therapeutic approaches, and risk factors associated with neurodegenerative processes. [1]
One of the hallmarks of neurodegeneration is the accumulation of misfolded proteins into insoluble aggregates. Each disease is characterized by a specific pathological protein: [2]
These misfolded proteins propagate in a prion-like manner, spreading from cell to cell and templating the misfolding of endogenous proteins [1]. [3]
Mitochondria are central to neuronal survival, providing energy through oxidative phosphorylation and regulating calcium homeostasis. In neurodegeneration, multiple mitochondrial defects occur: [4]
The brain's high metabolic rate and lipid content make it particularly vulnerable to oxidative damage. Reactive oxygen species (ROS) are generated from: [5]
Oxidative damage to DNA, proteins, and lipids contributes to neuronal dysfunction and death [3].
Chronic neuroinflammation is a universal feature of neurodegenerative diseases. Activated microglia release:
The blood-brain barrier (BBB) breakdown in neurodegeneration allows peripheral immune cell infiltration, exacerbating inflammation [4].
Excessive glutamate receptor activation leads to calcium influx and cytotoxic signaling:
Excitotoxicity is particularly prominent in ALS and stroke, but contributes to all neurodegenerative conditions [5].
The most common cause of dementia, affecting over 50 million people worldwide. AD is characterized by:
The second most common neurodegenerative disease, characterized by:
A fatal motor neuron disease with rapid progression:
An autosomal dominant trinucleotide repeat disorder:
Neurodegeneration represents a complex interplay of genetic susceptibility, protein pathology, metabolic dysfunction, and environmental factors. While disease-modifying therapies remain elusive, significant advances in biomarker development, understanding of disease mechanisms, and therapeutic targeting offer hope for future treatments. Early diagnosis through biomarkers and personalized intervention based on genetic and molecular profiling will likely transform clinical management of these devastating disorders.
This section highlights recent publications relevant to this disease.
Bilateral hypertensive retinopathy (grade 4): Case report and review of the literature on intravitreal injection anti-VEGF therapy. ↩︎
Harnessing nature: a systematic exploration of in vitro antileishmanial and antihuman African trypanosomal properties in traditional medicinal plants and their active principles. ↩︎
GPR3 in neuro-metabolic-immune-reproductive nexus - a potential therapeutic target for Multi-System diseases. ↩︎
Targeting CXCL8 in post-traumatic stress disorder and Alzheimer's disease: insights from cross-disorder molecular analysis. ↩︎
Superoxide-responsive mitochondria-targeting peptide-persulfide donor conjugate for retinal ganglion cells protection in glaucoma. ↩︎